Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can we predict which kids will respond to migraine drug?

NCT ID NCT07180043

Knowledge-focused Sponsor: Kayseri University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This completed study in 178 children aged 6-16 with migraine compared the drug propranolol to structured behavioral therapy. Researchers looked for clinical and biochemical factors that might predict who responds best to propranolol. The goal is to help personalize migraine prevention in children.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
propranolol
What this could lead to
If successful, this could help doctors predict which children with migraine will benefit most from propranolol, leading to more personalized treatment.
What could go wrong
This is an observational study, not a randomized trial, so results may not prove cause and effect. The findings are also specific to children aged 6-16 and may not apply to others.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

178 people

The number who actually took part.

Started

Jan 2021

Finished

Dec 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

6 to 16 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of primary migraine (with or without aura) according to ICHD-3 criteria * Age between 6 and 16 years * Minimum of 4 migraine attacks per month * No history of prophylactic migraine therapy within the last 3 months * Written informed consent obtained from parents or legal guardians Exclusion Criteria: * Secondary headaches due to underlying pathologies (e.g., tumors, infections, vascular malformations) * Chronic systemic or psychiatric disorders (e.g., epilepsy, major depression) * Contraindications to propranolol (e.g., asthma, cardiac conduction defects) * Incomplete clinical data or loss to follow-up

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Headache disorders are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

headache disorder migraine disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Headache disorders Pediatric migraine

Contacts and locations

Locations

  • Kayseri University

    Kayseri, Kayseri, 38130, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.